Inici › Mieloma múltiple › Florida › Tampa
Assaigs clínics de Mieloma múltiple a Tampa, FL
15 estudis de Mieloma múltiple busquen participants en centres de Tampa i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
ReclutantFase 1
- Moffitt Cancer Center /ID# 279068, Tampa
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ReclutantFase 3
- Research Site, Tampa
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 3
- Moffit Cancer center, Tampa
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
ReclutantFase 4
- Moffitt Cancer Center, Tampa
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- Moffitt Cancer Center, Tampa
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 2
- Moffitt Cancer Center, Tampa
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
ReclutantFase 1
- Moffitt Cancer Center, Tampa
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1/2
- Research Site, Tampa
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ReclutantFase 1/2
- Research Site, Tampa
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
ReclutantFase 3
- Research Site, Tampa
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
ReclutantFase 1/2
- Moffitt Cancer Center /ID# 272628, Tampa
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
ReclutantFase 3
- Moffitt at Memorial Healthcare System, Tampa
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1/2
- Moffitt Cancer Center - McKinley Drive, Tampa
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutantFase 1/2
- Moffitt Cancer Center, Tampa
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
ReclutantFase 1
- Moffitt Cancer Center, Tampa
Assaigs de Mieloma múltiple en altres ciutats
- New York City, NY60 estudis
- Boston, MA42 estudis
- Atlanta, GA41 estudis
- Houston, TX38 estudis
- Durham, NC37 estudis
- Nashville, TN32 estudis
- Denver, CO27 estudis
- Rochester, MN24 estudis
- St. Louis, MO24 estudis
- Columbus, OH24 estudis
- Baldwin Park, CA23 estudis
- Chicago, IL22 estudis
Altres estudis a Tampa
- Càncer de pulmó de cèl·lules no petites51 estudis
- Càncer de mama43 estudis
- Càncer (tots els tipus)39 estudis
- Càncer colorrectal33 estudis
- Càncer metastàtic29 estudis
- Càncer de pulmó29 estudis
- Leucèmia mieloide aguda29 estudis
- Càncer de pàncrees26 estudis
- Càncer d'ovari21 estudis
- Síndromes mielodisplàsiques19 estudis
- Melanoma19 estudis
- Insuficiència cardíaca18 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.